|Bid||10.95 x 3200|
|Ask||11.84 x 1100|
|Day's Range||11.11 - 11.36|
|52 Week Range||6.26 - 19.25|
|Beta (3Y Monthly)||2.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.50|
Sandy Macrae has been the CEO of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) since 2016. This analysis aims first to...
Sangamo (SGMO) delivered earnings and revenue surprises of 25.71% and -9.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today that CEO Sandy Macrae will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City. The Wedbush presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Earlier in the week, Dr. Macrae will participate in the BTIG Biotechnology Conference 2019 in a panel discussion, “Exploring the Novel Approaches to Treating Sickle Cell Disease”.
BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately. Mr. Loeb will oversee all legal matters for Sangamo and will report to the Chief Executive Officer. “Gary brings dynamic experience in pharmaceutical compliance, legal operations, and executive leadership,” said Sandy Macrae, Sangamo's Chief Executive Officer.
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today that the Company will release its second quarter 2019 financial results after the market closes on Wednesday, August 7, 2019. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today the publication in Nature Biotechnology of a manuscript by Jeffrey Miller, Ph.D., and colleagues at Sangamo, describing two new strategies for optimizing the specificity of genome editing using zinc finger nucleases (ZFNs). The ability to engineer highly specific gene editing nucleases with little or no detectable activity at unintended genomic sequences is a key safety factor for therapeutic applications. The strategies entail engineering the two key functional regions within the ZFN structure, namely adjusting the binding affinity of the zinc finger array which recognizes DNA, and slowing the catalytic rate of the Fok1 cleavage domain.
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
On Friday last week, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced promising updated results from the Phase 1/2 ALTA trial.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Soliton, Inc. (NASDAQ: SOLY ) shares were ...
Sangamo Therapeutics reported positive data on its gene therapy for hemophilia, and CannTrust Holdings received a noncompliance report from Canadian authorities.
Sangamo stock popped Monday after the biotech company unveiled promising results for its Pfizer-partnered gene therapy in hemophilia A treatment. Sangamo stock jumped as much as 16.9%.
Sangamo Therapeutics (NASDAQ:SGMO) stock was on the up and up to kick off the week as the business revealed that it has made some key forward progress in its gene therapy that is designed to treat hemophilia A.Source: Shutterstock The Richmond, Calif.-based business revealed on Friday -- along with its partner Pfizer (NYSE:PFE) -- updated data from its Phase I/II Alta study of SB-525, designed to treat the aforementioned blood ailment. The data was presented in Melbourne, Australia, which hosts the International Society on Thrombosis and Haemostasis congress.Sangamo and Pfizer highlighted data that showed, out of the four patients who were given the highest dose of 30 trillion vectors per kilogram, two of them rapidly experienced positive results. They attained normal and sustained levels of Factor VIII with no reported bleeding events or need to receive treatment with the factor for as long as 24 weeks.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe other two experienced Factor VIII activity kinetics that was consistent with the first two patients. Sangamo had presented interim data on eight patients that the biotechnology company treated with SB-525 in April, which indicated that the therapy was well-tolerated-the data also showed a dose-dependent increase in Factor VIII levels across the dosage cohorts.The California business was founded in 1995 and it focuses its treatments on helping patients with hemophilia and other genetic illnesses.SGMO stock is up about 3.5% on Monday following the news. More From InvestorPlace * 7 A-Rated Stocks to Buy for the Rest of 2019 * The 7 Top Small-Cap Stocks Of 2019 * 7 F-Rated Stocks to Sell for Summer * 7 Retail Stocks to Buy That Are Down in 2019 The post Sangamo Therapeutics News: SGMO Stock Surges on Gene Therapy Study appeared first on InvestorPlace.
Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.
BRISBANE, Calif. & NEW YORK-- -- The first two patients treated at the 3e13 vg/kg dose level rapidly achieved normal, sustained Factor VIII levels with no reported bleeding events and no factor usage for as long as 24 weeks of follow-up The two patients more recently treated at the 3e13 vg/kg dose level demonstrated FVIII activity kinetics that appear consistent with the first two patients in this ...
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...